Send me real-time posts from this site at my email
Zacks

BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue